A landmark regulatory win headlined Monday's session, with AstraZeneca securing FDA approval for Truqap as the first targeted therapy for a specific form of prostate cancer, a milestone that adds a new indication to one of the FTSE 100's largest drug portfolios. Elsewhere, gene-therapy specialist 4basebio bolstered its advisory ranks, and self-storage group Big Yellow recycled capital from a property disposal into a twelve-store expansion programme.
4basebio adds synthetic DNA expert to advisory board
4basebio appointed Dr Jeff Coller to its Strategic Advisory Board, effective 15 June, to guide the company's efforts to scale synthetic DNA manufacturing across mRNA, AAV vector and gene-editing applications. Coller's expertise is intended to support 4basebio's positioning as a supplier of high-quality synthetic DNA to the broader nucleic acid therapeutics industry. No stock price data was available for 4basebio at the time of publication.
AstraZeneca's Truqap becomes first targeted therapy for PTEN-deficient prostate cancer
AstraZeneca (LON:AZN) announced that the US Food and Drug Administration has approved Truqap (capivasertib) as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer, a genetically defined patient population with prior options. The approval marks a significant expansion of Truqap's label, which already covers certain breast cancer indications, and cements capivasertib's role as a cornerstone of AstraZeneca's oncology pipeline. Shares in AstraZeneca traded at 13,354p, down 0.8% on the session, with the modest dip likely reflecting broader market moves rather than any scepticism about the approval itself.
